Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15289017 | 0.84 | RIPK1 (0.37) | IDO1AGXTPTGS2RIPK1TRPC5 | |
| SCHEMBL7667398 | 0.80 | IDO1 (0.37) | IDO1AGXTPTGS2RIPK1 | |
| SCHEMBL27748635 | 0.79 | PSEN1 (0.38) | IDO1AGXTPTGS2PSEN1PSEN2 | |
| SCHEMBL28781489 | 0.78 | IDO1 (0.36) | IDO1AGXTPTGS2 | |
| SCHEMBL16425423 | 0.78 | IDO1 (0.36) | IDO1AGXTPTGS2RIPK1 | |
| SCHEMBL1381639 | 0.77 | IDO1 (0.50) | IDO1AGXTRIPK1KDM4ESMN1; SMN2 | |
| SCHEMBL518007 | 0.76 | IDO1 (0.54) | IDO1AGXTRIPK1KDM4ESMN1; SMN2 | |
| SCHEMBL27748959 | 0.76 | IDO1 (0.34) | IDO1AGXTPTGS2 | |
| SCHEMBL28625612 | 0.73 | ALDH1A1 (0.46) | IDO1AGXTPTGS2KDM4E | |
| SCHEMBL31490495 | 0.73 | IDO1 (0.38) | IDO1AGXTPTGS2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | IDO1 2778/4885AGXT 441/4885PTGS2 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.